- Home
- MPB vs AKBA Comparison
MPB vs AKBA Comparison
Compare MPB & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- AKBA
- Stock Information
- Founded
- MPB 1868
- AKBA 2007
- Country
- MPB United States
- AKBA United States
- Employees
- MPB N/A
- AKBA N/A
- Industry
- MPB Major Banks
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- AKBA Health Care
- Exchange
- MPB Nasdaq
- AKBA Nasdaq
- Market Cap
- MPB 655.5M
- AKBA 729.1M
- IPO Year
- MPB N/A
- AKBA 2014
- Fundamental
- Price
- MPB $29.26
- AKBA $1.56
- Analyst Decision
- MPB Buy
- AKBA Strong Buy
- Analyst Count
- MPB 1
- AKBA 6
- Target Price
- MPB $37.00
- AKBA $6.25
- AVG Volume (30 Days)
- MPB 76.4K
- AKBA 5.1M
- Earning Date
- MPB 10-22-2025
- AKBA 11-10-2025
- Dividend Yield
- MPB 3.00%
- AKBA N/A
- EPS Growth
- MPB N/A
- AKBA N/A
- EPS
- MPB 2.40
- AKBA N/A
- Revenue
- MPB $208,869,000.00
- AKBA $225,071,000.00
- Revenue This Year
- MPB $26.19
- AKBA $53.38
- Revenue Next Year
- MPB $28.25
- AKBA $30.53
- P/E Ratio
- MPB $12.19
- AKBA N/A
- Revenue Growth
- MPB 20.73
- AKBA 32.49
- 52 Week Low
- MPB $22.50
- AKBA $1.49
- 52 Week High
- MPB $32.84
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- MPB 54.13
- AKBA 31.15
- Support Level
- MPB $27.98
- AKBA $1.52
- Resistance Level
- MPB $29.89
- AKBA $1.65
- Average True Range (ATR)
- MPB 0.62
- AKBA 0.12
- MACD
- MPB 0.06
- AKBA 0.01
- Stochastic Oscillator
- MPB 68.32
- AKBA 18.75
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.